(Note: Capital Investment Corp. VI withdrew its SPAC IPO prospectus in an SEC filing dated March 4, 2022; the SPAC had filed plans to go public in February 2021.) Mark Ein and Dyson Dryden have established Capitol Investment Corp. VI, their sixth blank check company, to invest in and help build an industry-leading public company that […]

We are a health-focused technology company developing simple, smart and personalized devices designed to help individuals on their health journey maintain good health today and prevent and manage chronic diseases in the future. We are developing a proprietary platform that uses Radio Frequency (“RF”) technology, which we believe will enable the creation of low-cost and […]

This is the second blank-check company or SPAC created by Sir Richard Branson, the founder of the Virgin Group. (This SPAC is incorporated in the Cayman Islands.) Our company’s founder is Sir Richard Branson, the founder of the Virgin Group and a renowned global entrepreneur. Virgin is a leading international investment group and one of […]

We are a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Since we commenced operations in 2016, we have discovered or developed five oncology programs that include four product candidates in either IND-enabling studies or clinical development. Our lead targeted oncology product candidate is IK-930, an […]

(IPOScoop has No Call on this deal because it is an uplift to the NASDAQ from the Johannesburg Stock Exchange (JSE). The ordinary shares of Karooooo’s subsidiary, Cartrack Holdings Ltd., trade under the symbol “CTK” on the JSE.) We offer a comprehensive, cloud-based smart mobility platform for connected vehicles, including electric vehicles (EVs). Our software-as-a-service […]

Our vision is to improve the lives of patients and families suffering from rare muscle disorders, including Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), by building the world’s leading muscle-focused, precision medicine company. In less than four years, we have matured into a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing drugs to treat […]

We are a preclinical-stage biopharmaceutical company pioneering novel small-molecule therapeutic candidates, called gene targeted chimeras (GeneTACs), that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. Certain nucleotide repeat expansion diseases, such as Friedreich ataxia (FA), can result in reduced expression of specific mRNAs; in other diseases, such […]

We are a pharmaceutical company based in Jiangxi, China, specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives (“TCMD”) products targeting the elderly with the goal of addressing their physical conditions in the aging process and to promote their general well-being. We have registered and obtained approval for 26 varieties of […]

(Note: This is a SPAC offering of ordinary shares and NOT units; most SPACs are unit offerings. This is the third special purpose acquisition company, or SPAC, also known as a blank-check company, created by Dragoneer Investment Group, whose early-stage investments have included Airbnb, Alibaba, DoorDash, Slack, Snowflake, Spotify and Uber. Incorporated in the Cayman […]

(Khosla Ventures Acquisition Co. III is offering shares of Class A common stock. This is not your typical SPAC unit offering.) We intend to focus our search for a target business addressing a large market opportunity with a highly differentiated, proprietary technology. (Note: Khosla Ventures Acquisition Co. III priced its SPAC IPO on March 23, […]